Glucotrack (NASDAQ: GCTK) advances implantable CBGM with IDE plan and new patents
Rhea-AI Filing Summary
Glucotrack, Inc. outlined clinical and operational progress that supports its plan to submit an Investigational Device Exemption (IDE) to the FDA for its implantable continuous blood glucose monitoring (CBGM) system in Q2 2026, aiming to start a U.S. clinical trial in the second half of 2026, subject to FDA approval.
The company completed a 5‑day first‑in‑human study in Brazil with 10 participants, achieving a Mean Absolute Relative Difference of 7.7% across 122 matched pairs, 99% data capture, and no procedure or device‑related serious adverse events. A follow‑on feasibility trial in Australia produced similar performance and informed protocol and product refinements.
Glucotrack also secured a U.S. trial site, engaged a CRO experienced in diabetes medtech, and completed targeted design iterations. In 2025 it was awarded three U.S. patents (US 12,453,494; US 12,458,257; US 12,458,258) covering sensor chemistry, intravascular lead design, and low‑power electronics for its three‑year longevity CBGM platform.
Positive
- None.
Negative
- None.
Insights
Glucotrack advances CBGM program toward U.S. IDE submission with supportive early data and patents.
Glucotrack describes a staged progression for its implantable CBGM: first‑in‑human data from Brazil, feasibility work in Australia, and preparation for a U.S. IDE filing in Q2 2026. The Brazilian 5‑day study showed a Mean Absolute Relative Difference of 7.7% across 122 paired readings and 99% data capture, supporting accuracy and reliability claims.
The company reports no procedure or device‑related serious adverse events in that study, an important early safety signal for an intravascular, long‑term implant. A secured U.S. trial site, engagement of a diabetes‑focused CRO, and product design iterations indicate operational readiness for the planned U.S. trial, although initiation remains subject to FDA IDE approval.
Management highlights three U.S. patents issued in October and November 2025 covering sensor chemistry, intravascular lead design, and low‑power electronics for a three‑year sensor longevity system. Future company disclosures about the IDE submission, FDA feedback, and timing of the planned U.S. trial start in the second half of 2026 will clarify regulatory and development momentum.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On March 27, 2026, Glucotrack, Inc., a Delaware corporation (the “Company”), issued a press release (the “Press Release”). The Press Release is furnished herewith as Exhibit 99.1.
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated March 27, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: March 27, 2026 | ||
| GLUCOTRACK, INC. | ||
| By: | /s/ Paul Goode | |
| Name: | Paul Goode | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Experience From Brazilian and Australian Clinical Trials Positions the Company to Submit Investigational Device Exemption (IDE) to FDA for Novel CBGM Technology in Q2 2026
Rutherford, NJ, March 27, 2026 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today provided a comprehensive recap of the critical operational milestones which have positioned the Company to submit an IDE to the U.S. Food and Drug Administration (FDA) for its novel continuous blood glucose monitoring (CBGM) technology, with a goal to file requisite documents with the FDA during Q2 of 2026.
“In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation,” commented Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “The completion of our first-in-human study in Brazil and initiation of our follow up study in Australia enables us to advance toward our U.S. clinical program. With trial infrastructure in place and product enhancements completed, we are prepared to initiate the study, pending FDA approval.”
“In parallel, we have continued to strengthen the commercial and operational foundation of the business,” Dr. Goode added. “We have completed extensive U.S. market research across patients and multiple healthcare provider segments, which indicates an unmet need for a fully implantable CBGM solution. Diabetes represents one of the largest addressable healthcare markets globally, with Continuous Glucose Monitor (CGM) among its fastest-growing and most dynamic segments. Our research indicates that our differentiated technology has the potential to deliver meaningful, scalable impact for millions of patients.”
“We have also identified a clear U.S. reimbursement pathway that supports a compelling economic profile, built a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners, and assembled a seasoned management team with deep experience in diabetes and implantable medical technologies from industry leaders such as Dexcom, Abbott, Senseonics, and Medtronic.”
“We are extremely proud of the accomplishments we achieved as a team in 2025, and we are prepared to execute further on the development of our first-to-market CBGM system to meet the needs of the millions of people living with diabetes in the US alone,” concluded Dr. Goode.
First In-Human Study
In Q1, the Company completed its first in-human clinical trial. The objective of this 5-day in-hospital study was to assess the insertion, use, and removal of the intravascular lead which was connected to externalized electronics.The study, which was conducted at the Interventional Cardiology at Instituto do Coração in São Paulo, Brazil between December 13, 2024 and January 31, 2025, included ten participants with either Type 1 or Type 2 diabetes who were on intensive insulin therapy. The insertion and removal procedures were performed by interventional cardiologists using established percutaneous techniques.
Detailed analysis showed consistent performance during glucose tolerance testing with minimal lag time compared to venous blood samples. The study met all primary and secondary endpoints, demonstrating excellent accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, a 99% data capture rate, and no procedure or device-related serious adverse events. These findings support the safety and performance of the Company’s long-term, implantable CBGM, which measures glucose from blood rather than interstitial fluid, eliminating the typical lag time associated with traditional continuous glucose monitoring systems.
Australia Clinical Trial
In July 2025, the Company initiated a feasibility clinical trial at the Diabetes Technology Research Group of St Vincent’s Hospital in Melbourne, Australia. While the system performance was similar to that observed in the Brazilian trial, this study provided meaningful protocol and product learnings which have been incorporated for the next planned clinical study (discussed below).
US Clinical Trial Readiness
Following the completion of these trials, the Company has completed several key clinical trial readiness activities for its planned U.S. clinical study. A U.S. clinical trial site has been secured, and a Clinical Research Organization (CRO) experienced with diabetes Medtech has been engaged to manage and conduct the study. In parallel, the Company has completed targeted product design iterations to further enhance functionality and performance. With these foundational elements in place, the Company is currently engaged in discussions with the FDA regarding its planned U.S. clinical trial program. Glucotrack expects to be positioned to initiate the study in the second half of 2026, subject to FDA approval of its IDE submission.
Patents
In October and November 2025, the Company was successfully awarded three critical patents relating to the Company’s CBGM platform, a long-term implantable device designed for three-year sensor longevity, including proprietary sensor chemistry, intravascular lead design, and low-power electronics. The US Patent and Trademark Office (USPTO) issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company’s CBGM platform.
Together, these innovations bridge the gap between short-lived subcutaneous sensors and larger pacemaker-class devices, securing critical components of the Company’s intellectual property portfolio for the long-term. These three new patents were critical to securing and expanding the Company’s core intellectual property portfolio as it reinforces its go-to-market strategy.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on March 31, 2025.
Contacts:
| Investor Relations: | Media: |
| investors@glucotrack.com | GlucotrackPR@icrinc.com |
FAQ
What did Glucotrack (GCTK) announce in its latest 8-K filing?
What were the key results from Glucotrack’s first-in-human CBGM trial in Brazil?
How is Glucotrack preparing for its planned U.S. CBGM clinical trial?
What patents did Glucotrack secure for its CBGM platform in 2025?
How does Glucotrack’s CBGM system differ from traditional continuous glucose monitors?
What market opportunity is Glucotrack targeting with its CBGM technology?
Filing Exhibits & Attachments
5 documents